title: Oral deferiprone for iron chelation in people with thalassaemia.
abstract: BACKGROUND
  Thalassaemia major is a genetic disease characterised by a reduced ability to produce haemoglobin. Management of the resulting anaemia is through red blood cell transfusions.Repeated transfusions result in an excessive accumulation of iron in the body (iron overload), removal of which is achieved through iron chelation therapy. A commonly used iron chelator, deferiprone, has been found to be pharmacologically efficacious. However, important questions exist about the efficacy and safety of deferiprone compared to another iron chelator, desferrioxamine.
  
  
  OBJECTIVE
  To summarise data from trials on the clinical efficacy and safety of deferiprone and to compare the clinical efficacy and safety of deferiprone with desferrioxamine for thalassaemia.
  
  
  METHODS
  We searched the Cochrane Cystic fibrosis and Genetic Disorders Group's Haemoglobinopathies trials Register and MEDLINE, EMBASE, CENTRAL (The Cochrane Library), LILACS and other international medical databases, plus registers of ongoing trials and the Transfusion Evidence Library (www.transfusionevidencelibrary.com). We also contacted the manufacturers of deferiprone and desferrioxamine.All searches were updated to 05 March 2013.
  
  
  METHODS
  Randomised controlled trials comparing deferiprone with another iron chelator; or comparing two schedules or doses of deferiprone, in people with transfusion-dependent thalassaemia.
  
  
  METHODS
  Two authors independently assessed trials for risk of bias and extracted data. Missing data were requested from the original investigators.
  
  
  RESULTS
  A total of 17 trials involving 1061 participants (range 13 to 213 participants per trial) were included. Of these, 16 trials compared either deferiprone alone with desferrioxamine alone, or a combined therapy of deferiprone and desferrioxamine with either deferiprone alone or desferrioxamine alone; one compared different schedules of deferiprone. There was little consistency between outcomes and limited information to fully assess the risk of bias of most of the included trials.Four trials reported mortality; each reported the death of one individual receiving deferiprone with or without desferrioxamine. One trial reported five further deaths in patients who withdrew from randomised treatment (deferiprone with or without desferrioxamine) and switched to desferrioxamine alone. Seven trials reported cardiac function or liver fibrosis as measures of end organ damage.Earlier trials measuring the cardiac iron load indirectly by magnetic resonance imaging (MRI) T2* signal had suggested deferiprone may reduce cardiac iron more quickly than desferrioxamine. However, a meta-analysis of two trials suggested that left ventricular ejection fraction was significantly reduced in patients who received desferrioxamine alone compared with combination therapy.  One trial, which planned five years of follow up, was stopped early due to the beneficial effects of combined treatment compared with deferiprone alone in terms of serum ferritin levels reduction.The results of this and three other trials suggest an advantage of combined therapy over monotherapy to reduce iron stores as measured by serum ferritin. There is, however, no conclusive or consistent evidence for the improved efficacy of combined deferiprone and desferrioxamine therapy over monotherapy from direct or indirect measures of liver iron. Both deferiprone and desferrioxamine produce a significant reduction in iron stores in transfusion-dependent, iron-overloaded people. There is no evidence from randomised controlled trials to suggest that either has a greater reduction of clinically significant end organ damage.Evidence of adverse events were observed in all treatment groups. Occurrence of any adverse event was significantly more likely with deferiprone than desferrioxamine in one trial, RR 2.24 (95% CI 1.19 to 4.23). Meta-analysis of a further two trials showed a significant increased risk of adverse events associated with combined deferiprone and desferrioxamine compared with desferrioxamine alone, RR 3.04 (95% CI 1.18 to 7.83). The most commonly reported adverse event was joint pain, which occurred significantly more frequently in patients receiving deferiprone than desferrioxamine, RR 2.64 (95% CI 1.21 to 5.77). Other common adverse events included gastrointestinal disturbances as well as neutropenia or leucopenia, or both.
  
  
  CONCLUSIONS
  In the absence of data from randomised controlled trials, there is no evidence to suggest the need for a change in current treatment recommendations; namely that deferiprone is indicated for treating iron overload in people with thalassaemia major when desferrioxamine is contraindicated or inadequate. Intensified desferrioxamine treatment (by either subcutaneous or intravenous route) or use of other oral iron chelators, or both, remains the established treatment to reverse cardiac dysfunction due to iron overload. Indeed, the US Food and Drug Administration (FDA) recently only gave support for deferiprone to be used as a last resort for treating iron overload in thalassaemia, myelodysplasia and sickle cell disease. However, there is evidence that adverse events are increased in patients treated with deferiprone compared with desferrioxamine and in patients treated with combined deferiprone and desferrioxamine compared with desferrioxamine alone. There is an urgent need for adequately-powered, high-quality trials comparing the overall clinical efficacy and long-term outcome of deferiprone with desferrioxamine.
authors: Systematic Review Initiative, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, Oxon, UK, OX3 9BQ.
authors: Sheila A
authors: SA
authors: Fisher
authors: Susan J
authors: SJ
authors: Brunskill
authors: Carolyn
authors: C
authors: Doree
authors: Onima
authors: O
authors: Chowdhury
authors: Sarah
authors: S
authors: Gooding
authors: David J
authors: DJ
authors: Roberts
mesh_terms: D000284:Administration, Oral; D015913:Chelation Therapy / Q000009:adverse effects*; D000077543:Deferiprone; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013789:Thalassemia / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D003676:Deferoxamine
references: Haematologica. 2006 Sep;91(9):1241-3
references: 16956824
references: Acta Haematol. 1990;84(3):113-7
references: 2123060
references: N Engl J Med. 1986 Apr 3;314(14):869-73
references: 3485251
references: Hemoglobin. 2003 May;27(2):63-76
references: 12779268
references: Br J Haematol. 1997 Sep;98(3):597-600
references: 9332313
references: Br J Haematol. 1992 Oct;82(2):431-6
references: 1419825
references: Clin Pharmacol Ther. 1994 Jan;55(1):70-5
references: 8299320
references: Lancet. 1983 Jul 23;2(8343):181-4
references: 6135026
references: Br J Haematol. 1995 Dec;91(4):827-33
references: 8547125
references: BMC Blood Disord. 2002 Nov 20;2(1):4
references: 12441006
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: Br J Haematol. 2003 Apr;121(1):187-9
references: 12670352
references: Br J Haematol. 1990 Oct;76(2):295-300
references: 2094333
references: Hematology. 2012 May;17(3):183-6
references: 22664119
references: Ann N Y Acad Sci. 1998 Jun 30;850:223-6
references: 9668543
references: Health Qual Life Outcomes. 2006 Sep 28;4:73
references: 17007645
references: Blood. 2002 Sep 1;100(5):1566-9
references: 12176871
references: Eur J Haematol. 2003 Jun;70(6):392-7
references: 12756022
references: Ann N Y Acad Sci. 1990;612:369-77
references: 2291564
references: N Engl J Med. 1977 Aug 25;297(8):418-23
references: 882111
references: Lancet. 2002 Aug 17;360(9332):516-20
references: 12241655
references: Blood. 2007 Jun 15;109(12):5157-9
references: 17344464
references: Arch Iran Med. 2009 Sep;12(5):488-91
references: 19722772
references: Transfus Sci. 2000 Dec;23(3):239-40
references: 11099900
references: Hematology. 2007 Dec;12(6):577-85
references: 17852442
references: Aust N Z J Med. 1993 Dec;23(6):656-61
references: 8141693
references: Hemoglobin. 2011;35(3):206-16
references: 21599433
references: N Engl J Med. 1995 Apr 6;332(14):918-22
references: 7877649
references: Indian Pediatr. 2004 Jan;41(1):21-7
references: 14767084
references: Vox Sang. 2010 Jul;99 Suppl 1:1-516
references: 20591082
references: Haematologica. 2004 Oct;89(10):1187-93
references: 15477202
references: J Cardiovasc Magn Reson. 2011 Jul 06;13:34
references: 21733147
references: Circulation. 2007 Apr 10;115(14):1876-84
references: 17372174
references: N Engl J Med. 1998 Aug 13;339(7):417-23
references: 9700174
references: Haematologica. 2003 Dec;88(12):1423-5
references: 14687998
references: Br J Haematol. 2008 Jun;141(6):882-90
references: 18355381
references: Lancet. 2003 Jan 11;361(9352):182-3; author reply 183-4
references: 12531618
references: Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196-208
references: 12064916
references: N Engl J Med. 1986 Jun 19;314(25):1643
references: 3713766
references: Acta Haematol. 2003;110(4):224-6
references: 14663175
references: Hemoglobin. 2006;30(2):263-74
references: 16798652
references: Lancet. 1978 Jun 3;1(8075):1178-81
references: 77945
references: Br J Haematol. 2009 Apr;145(2):245-54
references: 19236376
references: Br J Haematol. 1989 Nov;73(3):403-9
references: 2605127
references: Ann Hematol. 2012 Sep;91(9):1443-9
references: 22572843
references: Haematologica. 2000 Feb;85(2):115-7
references: 10681716
references: J Pediatr. 1991 Apr;118(4 Pt 1):540-5
references: 2007928
references: Blood. 2003 Sep 1;102(5):1583-7
references: 12763939
references: J Cardiovasc Magn Reson. 2008 Feb 25;10:12
references: 18298856
references: Blood. 2006 May 1;107(9):3738-44
references: 16352815
references: Br J Haematol. 1992 Oct;82(2):460-6
references: 1419829
references: Best Pract Res Clin Haematol. 2002 Jun;15(2):329-68
references: 12401311
references: Blood. 1998 Jan 1;91(1):295-300
references: 9414297
references: ISRN Hematol. 2012;2012:139862
references: 23316378
references: Br J Haematol. 1998 Jun;101(3):413-5
references: 9633879
references: Eur J Haematol. 2010 Jul;85(1):36-42
references: 20331740
references: J Clin Invest. 1983 Mar;71(3):429-39
references: 6826715
references: N Engl J Med. 1994 Sep 1;331(9):574-8
references: 8047081
references: Hematology. 1999;4(1):67-76
references: 11399554
references: Hemoglobin. 2010;34(1):95-106
references: 20113293
references: Haematologica. 2008 May;93(5):741-52
references: 18413891
references: Lancet. 1990 Nov 24;336(8726):1275-9
references: 1978115
references: Acta Haematol. 2000;104(2-3):99-102
references: 11154982
references: N Engl J Med. 1994 Sep 1;331(9):567-73
references: 8047080
references: Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51
references: 19233692
references: N Engl J Med. 1985 Jun 20;312(25):1600-3
references: 4000198
references: Ann Hematol. 2008 Jul;87(7):545-50
references: 18351337
references: Eur J Haematol. 1988 Apr;40(4):380-1
references: 3366230
references: Lancet. 2000 Jun 10;355(9220):2051-2
references: 10885361
references: Acta Haematol. 1996;95(1):26-36
references: 8604584
references: Br J Haematol. 2002 Jul;118(1):330-6
references: 12100170
references: Int J Pediatr Otorhinolaryngol. 1996 May;35(3):223-30
references: 8762595
references: Int J Epidemiol. 2002 Feb;31(1):140-9
references: 11914310
references: N Engl J Med. 1999 Jul 8;341(2):99-109
references: 10395635
references: J Med Ethics. 2004 Feb;30(1):1-7
references: 14872065
references: Ann N Y Acad Sci. 1998 Jun 30;850:227-31
references: 9668544
references: Blood. 2006 May 1;107(9):3436-41
references: 16627763
references: Blood Cells Mol Dis. 2011 Oct 15;47(3):166-75
references: 21843958
references: Hemoglobin. 2010 Jun;34(3):305-21
references: 20524820
references: Eur J Haematol. 2007 Jan;78(1):48-51
references: 17042774
references: Eur J Haematol. 2001 Jul;67(1):30-4
references: 11553264
references: Am J Hematol. 2012 Jul;87(7):732-3
references: 22622672
references: Br Med J (Clin Res Ed). 1987 Dec 12;295(6612):1509-12
references: 3122880
references: N Engl J Med. 2002 Oct 24;347(17):1368-71
references: 12397199
references: Eur J Haematol. 2006 Mar;76(3):183-92
references: 16451393
references: Haematologica. 2012 Jun;97(6):835-41
references: 22180427
references: Blood Cells Mol Dis. 2010 Aug 15;45(2):136-9
references: 20678715
references: Blood Cells Mol Dis. 2004 Jan-Feb;32(1):139-40; author reply 141-2
references: 14757428
references: Hematology Am Soc Hematol Educ Program. 2001;:47-61
references: 11722978
references: Baillieres Clin Haematol. 1989 Apr;2(2):459-74
references: 2660937
references: Blood. 1997 Feb 1;89(3):739-61
references: 9028304
references: Semin Hematol. 1990 Apr;27(2):101-4
references: 2190316
references: Eur J Haematol. 1999 Oct;63(4):267-8
references: 10530416
references: Indian J Pediatr. 2004 Mar;71(3):213-6
references: 15080407
references: Blood. 1992 May 15;79(10):2741-8
references: 1586721
references: Haematologica. 2007 Dec;92(12):1599-606
references: 18055982
references: Br J Haematol. 2007 Aug;138(4):407-21
references: 17659052
references: Br J Haematol. 1990 Dec;76(4):550-3
references: 2265118
references: Haematologica. 2004 Apr;89(4):ELT07
references: 15075120
references: Cochrane Database Syst Rev. 2013 Aug 21;(8):CD004450
references: 23963793
references: Mutagenesis. 2003 Sep;18(5):457-63
references: 12960415
references: Hemoglobin. 2006;30(2):257-62
references: 16798651
references: Haematologica. 1998 Jun;83(6):496-501
references: 9676021
references: J Pediatr Hematol Oncol. 2007 Sep;29(9):598-601
references: 17805032
references: N Engl J Med. 1976 Jun 24;294(26):1421-3
references: 1272274
references: Br J Haematol. 2003 Jun;121(6):938-48
references: 12786807
references: Ceylon Med J. 2002 Dec;47(4):119-21
references: 12661341
references: J Cardiovasc Magn Reson. 2013 Jan 16;15:1
references: 23324167
references: J Cardiovasc Magn Reson. 2012 Jan 25;14:8
references: 22277065
references: Blood. 2003 Jun 15;101(12):5089-90; author reply 5090-1
references: 12788794
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120